Hongping Lu
Hongping Lu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Jun Cheng
Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
2 shared publications Kai Han
Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
1 shared publicationKelbinur Tursun
Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
1 shared publicationLi Zhou
Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
1 shared publication- Mengran Zhang
Gastroenterology Department, Xuanwu Hospital Capital Medical University, Beijing, China
1 shared publication Ming Han
Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 58, e14540
Pitavastatin reduces intestinal fibrosis in chronic colitis and inhibits colon fibroblast activation by enhancing MMP-9 expression via the IGF-1/IGF-1R pathway
Statins have been shown to have antifibrotic effects on various tissues and organs, but their ability to improve chronic colitis-associated intestinal fibrosis and their mechanisms of action remain unclear. The objective of this study was to investigate the role of pitavastatin in chronic colitis-associated intestinal fibrosis and its possible mechanisms. We established a mouse model of chronic colitis-associated intestinal fibrosis through repeated administration of dextran sodium sulfate (DSS) and treated the mice with pitavastatin. The severity of intestinal fibrosis, serum inflammatory factor levels, and expression levels of intestinal fibrosis-related genes in mice were assessed using pathological histological staining, immunohistochemical staining, reverse-transcription PCR, RNA sequencing, and enzyme-linked immunosorbent assay. In vitro, we treated a human colon fibroblast cell line (CCD-18Co) with or without transforming growth factor-β1 stimulation using pitavastatin. Western blot, Cell Counting Kit-8 assay, and Transwell assay were used to analyze the activation of colonic fibroblasts, protein expression levels of genes related to intestinal fibrosis, and cell proliferation and migration abilities. Pitavastatin significantly attenuated DSS-induced chronic colitis and intestinal fibrosis. In vitro, pitavastatin concentration-dependently inhibited the activation of CCD-18Co cells, significantly reduced the expression levels of the intestinal fibrosis-related proteins Col1A1, IGF-1, IGF-1R, MMP-3, and TIMP-1, and significantly inhibited cell proliferation and migration while markedly increasing MMP-9 protein expression. Additionally, after silencing the IGF-1 and IGF-1R genes in CCD-18Co cells, the promotion of MMP-9 expression by pitavastatin was significantly inhibited. These findings suggest that pitavastatin may be a promising antifibrotic drug for future treatment of intestinal fibrosis.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 58, e14540
Open AccessPitavastatin reduces intestinal fibrosis in chronic colitis and inhibits colon fibroblast activation by enhancing MMP-9 expression via the IGF-1/IGF-1R pathway
Statins have been shown to have antifibrotic effects on various tissues and organs, but their ability to improve chronic colitis-associated intestinal fibrosis and their mechanisms of action remain unclear. The objective of this study was to investigate the role of pitavastatin in chronic colitis-associated intestinal fibrosis and its possible mechanisms. We established a mouse model of chronic colitis-associated intestinal fibrosis through repeated administration of dextran sodium sulfate (DSS) and treated the mice with pitavastatin. The severity of intestinal fibrosis, serum inflammatory factor levels, and expression levels of intestinal fibrosis-related genes in mice were assessed using pathological histological staining, immunohistochemical staining, reverse-transcription PCR, RNA sequencing, and enzyme-linked immunosorbent assay. In vitro, we treated a human colon fibroblast cell line (CCD-18Co) with or without transforming growth factor-β1 stimulation using pitavastatin. Western blot, Cell Counting Kit-8 assay, and Transwell assay were used to analyze the activation of colonic fibroblasts, protein expression levels of genes related to intestinal fibrosis, and cell proliferation and migration abilities. Pitavastatin significantly attenuated DSS-induced chronic colitis and intestinal fibrosis. In vitro, pitavastatin concentration-dependently inhibited the activation of CCD-18Co cells, significantly reduced the expression levels of the intestinal fibrosis-related proteins Col1A1, IGF-1, IGF-1R, MMP-3, and TIMP-1, and significantly inhibited cell proliferation and migration while markedly increasing MMP-9 protein expression. Additionally, after silencing the IGF-1 and IGF-1R genes in CCD-18Co cells, the promotion of MMP-9 expression by pitavastatin was significantly inhibited. These findings suggest that pitavastatin may be a promising antifibrotic drug for future treatment of intestinal fibrosis.
- 11 December 2017
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (12) , 9312-9319
Role of IL‐6‐mediated expression of NS5ATP9 in autophagy of liver cancer cells
This study aimed to investigate the relationship between interleukin‐6 (IL‐6) and NS5ATP9 in autophagy of liver cancer cells. Autophagy is one of the important regulators of the replication of hepatitis C virus and the survival of tumors. IL‐6 is a multifunctional cytokine that plays an important role in autophagy and development of many kinds of tumors. However, the role of IL‐6 in autophagy has not been fully explored. A previous study had shown that a novel gene, NS5ATP9, could modulate autophagy. The present study demonstrated that human IL‐6 recombinant protein induced autophagy of HepG2 cells. Conversely, autophagy decreased after IL‐6 was silenced or neutralized with monoclonal antibody against human IL‐6. In addition, NS5ATP9 was upregulated by IL‐6 via nuclear factor–kappaB activation, as detected by Western blot. Further studies indicated that the induction of autophagy by IL‐6 could be attenuated by silencing NS5ATP9. Interestingly, the expression of NS5ATP9, in turn, resulted in the upregulation of IL‐6. In conclusion, IL‐6 could induce autophagy by expressing NS5ATP9, while NS5ATP9 upregulated IL‐6 levels in turn, which further induced autophagy.
- 11 December 2017
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (12) , 9312-9319
Role of IL‐6‐mediated expression of NS5ATP9 in autophagy of liver cancer cells
This study aimed to investigate the relationship between interleukin‐6 (IL‐6) and NS5ATP9 in autophagy of liver cancer cells. Autophagy is one of the important regulators of the replication of hepatitis C virus and the survival of tumors. IL‐6 is a multifunctional cytokine that plays an important role in autophagy and development of many kinds of tumors. However, the role of IL‐6 in autophagy has not been fully explored. A previous study had shown that a novel gene, NS5ATP9, could modulate autophagy. The present study demonstrated that human IL‐6 recombinant protein induced autophagy of HepG2 cells. Conversely, autophagy decreased after IL‐6 was silenced or neutralized with monoclonal antibody against human IL‐6. In addition, NS5ATP9 was upregulated by IL‐6 via nuclear factor–kappaB activation, as detected by Western blot. Further studies indicated that the induction of autophagy by IL‐6 could be attenuated by silencing NS5ATP9. Interestingly, the expression of NS5ATP9, in turn, resulted in the upregulation of IL‐6. In conclusion, IL‐6 could induce autophagy by expressing NS5ATP9, while NS5ATP9 upregulated IL‐6 levels in turn, which further induced autophagy.